This is a study for patients who have been previously treated for NHL. The purpose of this study is to determine the safety and feasibility of double-target CART-19 and 20 cells to the patients with relapsed and refractory CD19+/CD20+ NHL.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Double-target CART-19 and 20 cells will be administered on day0 after completion of the chemotherapy.
patients will receive a standard pre-conditioning regime with cyclophosphamide 500mg/m2/day IV for 2 days(Day-3 to day-2).
Fludarabine 25mg/m2/day IV for 3 days (Day-4 to day-2).
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China
RECRUITINGsafety as assessed by the occurrence of study related adverse events
monitor the occurrence of study related adverse events
Time frame: from the date of recieving intravenous CART cells up to one month
objective response rate
the proportion of patients benefit from the therapy
Time frame: 28 days and 3 months after recieving intravenous CART cells
peripheral blood CART cell copy number
The highest concentration of CART cells in peripheral blood, the time to reach the highest concentration, and the area under the curve at 28 days after recieving intravenous CART cells
Time frame: from the date of recieving intravenous CART cells up to one month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.